Optimal management of taxane acute pain syndrome not clear
the ONA take:
Despite its prevalence in patients receiving taxane-based chemotherapies, taxane acute pain syndrome (TAPS) remains poorly researched with few studies have evaluated its optimal management, according to a systematic review published online ahead of print in the journal Supportive Care in Cancer.
TAPS is characterized by myalgias and arthralgias beginning 1 to 3 days and lasting 5 to 7 days after taxane-based chemotherapy.
Although it is known to negatively impact patients’ quality of life, the optimal management of TAPS is unclear.
Therefore, researchers at The Ottawa Hospital and University of Ottawa in Ontario, Canada, conducted a systematic review of treatment strategies for TAPS across all tumor sites.
Results showed that neither glutathione nor glutamine were superior to placebo for TAPS. Researchers found that amifostine, a cytoprotective adjuvant used in cancer chemotherapy and radiotherapy, reduced pain in 36% of patients, while gabapentin reduced taxane-induced arthralgias and myalgias in 90% of patients.
“If the management of patients is to be improved, more prospective trials are needed,” the authors conclude.
Despite its prevalence in patients receiving taxane-based chemotherapies, taxane acute pain syndrome remains poorly researched.
Sign Up for Free e-newsletters
- Incidence of Post-traumatic Stress Disorder High Among Patients With Cancer
- Long-Term Night Shift Work Associated With Cancer Risk in Women
- Distress, Neuroticism Predict Long-term Emotional Distress After Cancer Diagnosis
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- FDA Grants Breakthrough Therapy Designation to Lenvatinib Plus Pembrolizumab for RCC
- Bacteria in Probiotics Carry Potential Risks for Immunocompromised Patients
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Breast Cancer Deaths Decrease Sharply Since 2000
- Identifying the Psychosocial Needs of Young Adults With Metastatic Cancer
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|